Regulus Therapeutics Inc. (NASDAQ:RGLS) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead drug RGLS8429 in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
RGLS8429 is being investigated in a Phase 1 single-ascending dose study in healthy volunteers.
